SCHEMBL3040140

SCHEMBL3040140

O=C(O)c1scc2cc(Br)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
RXFP1 Q9HBX9 3/20 0.41
ALAD P13716 1/20 0.41
PIM1 P11309 1/20 0.41
FABP3 P05413 1/20 0.41
FABP2 P12104 1/20 0.41
FABP4 P15090 1/20 0.41
FABP5 Q01469 1/20 0.41
NPC1 O15118 1/20 0.38
GPR35 Q9HC97 3/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11089727 0.79 MCL1 (0.51) MCL1MEN1KMT2ARXFP1ALAD
SCHEMBL1101645 0.73 ALDH1A1 (0.45) MCL1MEN1KMT2AFABP3FABP2
SCHEMBL2092440 0.71 CYP2A6 (0.38) MCL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL2092442 0.69 CYP2A6 (0.37) MCL1MEN1KMT2ARXFP1NPC1
SCHEMBL498796 0.68 TBXAS1 (0.47) MEN1KMT2ARXFP1ALADNPC1
SCHEMBL4703130 0.68 RXFP1 (0.41) MEN1KMT2ARXFP1NPC1KDM4E
SCHEMBL10081752 0.67 PTPN1 (0.53) MCL1MEN1KMT2ARXFP1PIM1
SCHEMBL2895958 0.66 GPR35 (0.58) MCL1MEN1KMT2ARXFP1NPC1
SCHEMBL18050231 0.66 MCL1 (0.71) MCL1RXFP1NPC1GPR35KDM4E
SCHEMBL16693177 0.66 BCKDK (0.50) MCL1MEN1KMT2ARXFP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION 2010-09-02 US disclosed
EP-2049481-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SmithKline Beecham Corporation (US) 2009-04-22 EP disclosed
WO-2008021851-A2 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222345-A1 NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS OPRL1, OPRM1, OPRK1 MCL1 4379/4885MEN1 4829/4885KMT2A 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.